Geron Corporation GERN

US Biotechnology

$1.02 ▲ +2.36% (+$0.02)

⬆️ Above Yest. High

Open $0.98

Prev Close $1.00

Day Range $0.97 – $1.03

52W Range $0.84 – $2.01

Market Cap $641.98M

Beta 0.66

EPS (TTM) $-0.10

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1996-07-31
Shares Out.	642,470,000
Website	geron.com/ ↗
Phone	13026587581
Employees	258
Revenue	$60.2M
Gross Profit	$60.2M
Net Income	$1.4M
Free Cash Flow	-$91.2M
Total Assets	$527.1M
Total Liabilities	$300.4M
Equity	$226.7M

About Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Geron Corporation is a publicly traded company under the ticker symbol GERN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.